Rocket
Premium
Excel Add-In
International
Tools
Dashboard
Screener
Spinoffs
IPOs
Register
Alerts
Sign In
Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
AbCellera Biologics Inc. (ABCL)
Create:
Alert
All
|
News
|
Filings
Date Filed
Type
Description
10/12/2023
8-K
Quarterly results
08/03/2023
10-Q
Quarterly Report for the period ended June 30, 2023
08/03/2023
8-K
Quarterly results
Docs:
"
AbCellera Biologics Inc. Condensed Consolidated Statements of Income and
",
"
CO PY RI GH T
"
05/24/2023
8-K
Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs:
"
NEWS RELEASE AbCellera Partners with the Governments of Canada and British Columbia to Advance Drug Development Capabilities and Infrastructure
"
05/04/2023
10-Q
Quarterly Report for the period ended March 31, 2023
05/04/2023
8-K
Quarterly results
04/28/2023
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/28/2023
DEF 14A
Form DEF 14A - Other definitive proxy statements:
04/28/2023
ARS
Form ARS - Annual Report to Security Holders:
04/24/2023
SC 13D/A
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
02/21/2023
S-8
Form S-8 - Securities to be offered to employees in employee benefit plans:
02/21/2023
10-K
Annual Report for the period ended December 31, 2022
02/13/2023
SC 13G/A
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/06/2023
SC 13G/A
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/18/2023
SC 13G
Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
11/08/2022
10-Q
Quarterly Report for the period ended September 30, 2022
11/08/2022
8-K
Quarterly results
07/22/2022
10-K/A
Annual Report for the period ended December 31, 2021 [amend]
07/22/2022
POS AM
Form POS AM - Post-Effective amendments for registration statement:
07/06/2022
8-K
Quarterly results
06/30/2022
8-K
Quarterly results
06/21/2022
8-K
Quarterly results
05/10/2022
10-Q
Quarterly Report for the period ended March 31, 2022
05/10/2022
8-K
Quarterly results
04/28/2022
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/28/2022
DEF 14A
Form DEF 14A - Other definitive proxy statements:
02/25/2022
S-3ASR
Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers:
02/25/2022
POS AM
Form POS AM - Post-Effective amendments for registration statement:
02/25/2022
S-8
Form S-8 - Securities to be offered to employees in employee benefit plans:
02/25/2022
10-K
Annual Report for the period ended December 31, 2021
02/24/2022
8-K
Quarterly results
02/15/2022
424B3
Form 424B3 - Prospectus [Rule 424(b)(3)]:
02/15/2022
8-K
Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data
Docs:
"
Left: Side view of a model of bebtelovimab Fabs bound to SARS-CoV-2 spike protein mapped with key mutations from the Omicron variant of concern . Right:
"
02/14/2022
SC 13G/A
VIKING GLOBAL INVESTORS LP reports a 0% stake in AbCellera Biologics Inc.
Next >>
Rocket Data Systems, Inc. © 2019 |
Contact Us
|
Data Disclaimer
|
Terms of Use
|
Privacy